Show simple item record

dc.contributor.authorLee, BY*
dc.contributor.authorWedlock, PT*
dc.contributor.authorHaidari, LA*
dc.contributor.authorElder, K*
dc.contributor.authorPotet, J*
dc.contributor.authorManring, R*
dc.contributor.authorConnor, DL*
dc.contributor.authorSpiker, ML*
dc.contributor.authorBonner, K*
dc.contributor.authorRangarajan, A*
dc.contributor.authorHunyh, D*
dc.contributor.authorBrown, ST*
dc.date.accessioned2017-05-08T18:12:45Z
dc.date.available2017-05-08T18:12:45Z
dc.date.issued2017-04-25
dc.date.submitted2017-05-08
dc.identifier.citationEconomic Impact of Thermostable Vaccines. 2017 Vaccineen
dc.identifier.issn1873-2518
dc.identifier.pmid28455169
dc.identifier.doi10.1016/j.vaccine.2017.03.081
dc.identifier.urihttp://hdl.handle.net/10144/618906
dc.description.abstractWhile our previous work has shown that replacing existing vaccines with thermostable vaccines can relieve bottlenecks in vaccine supply chains and thus increase vaccine availability, the question remains whether this benefit would outweigh the additional cost of thermostable formulations.
dc.language.isoenen
dc.publisherElsevieren
dc.relation.urlhttp://www.sciencedirect.com/science/journal/0264410Xen
dc.rightsPublished by Elsevier Archived on this site with kind permission and copyright 200X from Elsevieren
dc.titleEconomic Impact of Thermostable Vaccinesen
dc.identifier.journalVaccineen
refterms.dateFOA2019-03-04T13:21:50Z
html.description.abstractWhile our previous work has shown that replacing existing vaccines with thermostable vaccines can relieve bottlenecks in vaccine supply chains and thus increase vaccine availability, the question remains whether this benefit would outweigh the additional cost of thermostable formulations.


Files in this item

Thumbnail
Name:
Lee BY et al - 2017 - Economic ...
Size:
430.6Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record